Trial Profile
A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy in Subjects With Partial Onset Seizures.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Carisbamate (Primary) ; Levetiracetam; Topiramate
- Indications Partial epilepsies
- Focus Adverse reactions; Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms CaReS
- Sponsors SK Life Science
- 05 Oct 2021 This trial has been completed in France (Global end date: 09 May 2010).
- 05 Oct 2021 This trial has been completed in France (Global end date: 09 May 2010).
- 28 Jun 2012 Janssen-Cilag and UCB added as associations as reported in the European Clinical Trials Database record.